Literature DB >> 16728904

The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders.

Aron N Starosta1, Robert F Leeman, Joseph R Volpicelli.   

Abstract

While the U.S. Food and Drug Administration has approved several medications for the treatment of alcohol-related problems, their use has not gained wide acceptance in the United States. Typically, patients with alcohol use disorders are only referred to psychosocial support (e.g., Alcoholics Anonymous). However, the use of pharmacotherapy may complement psychosocial treatments, as evidence shows that pharmacotherapy can improve treatment outcomes. The effectiveness of pharmacotherapy depends on patient compliance with taking the medication and the context in which the medication is administered. BRENDA is a psychosocial program designed specifically to be used by many types of healthcare providers, including primary care clinicians. Designed to enhance medication and treatment compliance, BRENDA is an ideal approach for use in conjunction with pharmacotherapy. The BRENDA approach has 6 components: 1) a biopsychosocial evaluation; 2) a report of findings from the evaluation given to the patient; 3) empathy; 4) addressing patient needs; 5) providing direct advice; and 6) assessing patient reaction to advice and adjusting the treatment plan as needed. This paper describes these components and discusses how the empirical support for each component is linked to the enhancement of medication compliance and the improvement of treatment outcomes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16728904      PMCID: PMC2764009          DOI: 10.1097/00131746-200603000-00003

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN: 1527-4160            Impact factor:   1.325


  62 in total

Review 1.  Advances in the psychosocial treatment of anxiety disorders. Implications for national health care.

Authors:  D H Barlow; C L Lehman
Journal:  Arch Gen Psychiatry       Date:  1996-08

2.  Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes.

Authors: 
Journal:  J Stud Alcohol       Date:  1997-01

3.  Moderating binge drinking: it is possible to change behaviour if you plan it in advance.

Authors:  V Murgraff; D White; K Phillips
Journal:  Alcohol Alcohol       Date:  1996-11       Impact factor: 2.826

Review 4.  Brief interventions for alcohol problems: a review.

Authors:  T H Bien; W R Miller; J S Tonigan
Journal:  Addiction       Date:  1993-03       Impact factor: 6.526

5.  The relationship of counselor and peer alliance to drug use and HIV risk behaviors in a six-month methadone detoxification program.

Authors:  S L Tunis; K L Delucchi; K Schwartz; P Banys; K L Sees
Journal:  Addict Behav       Date:  1995 May-Jun       Impact factor: 3.913

Review 6.  The role of the therapeutic alliance in psychotherapy.

Authors:  A O Horvath; L Luborsky
Journal:  J Consult Clin Psychol       Date:  1993-08

7.  Brief physician advice for problem alcohol drinkers. A randomized controlled trial in community-based primary care practices.

Authors:  M F Fleming; K L Barry; L B Manwell; K Johnson; R London
Journal:  JAMA       Date:  1997-04-02       Impact factor: 56.272

8.  Enhancing motivation for change in problem drinking: a controlled comparison of two therapist styles.

Authors:  W R Miller; R G Benefield; J S Tonigan
Journal:  J Consult Clin Psychol       Date:  1993-06

9.  A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression.

Authors:  B J Mason; J H Kocsis; E C Ritvo; R B Cutler
Journal:  JAMA       Date:  1996-03-13       Impact factor: 56.272

Review 10.  Enhancing retention in clinical trials of psychosocial treatments: practical strategies.

Authors:  K M Carroll
Journal:  NIDA Res Monogr       Date:  1997
View more
  29 in total

Review 1.  Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence.

Authors:  Andrew J Muzyk; Sarah K Rivelli; Jane P Gagliardi
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

Review 2.  Targeted opioid receptor antagonists in the treatment of alcohol use disorders.

Authors:  Mark J Niciu; Albert J Arias
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

3.  Mechanisms of symptom reduction in a combined treatment for comorbid posttraumatic stress disorder and alcohol dependence.

Authors:  Carmen P McLean; Yi-Jen Su; Edna B Foa
Journal:  J Consult Clin Psychol       Date:  2015-06

4.  Harm reduction with pharmacotherapy for homeless people with alcohol dependence: protocol for a randomized controlled trial.

Authors:  Susan E Collins; Andrew J Saxon; Mark H Duncan; Brian F Smart; Joseph O Merrill; Daniel K Malone; T Ron Jackson; Seema L Clifasefi; Jutta Joesch; Richard K Ries
Journal:  Contemp Clin Trials       Date:  2014-05-17       Impact factor: 2.226

5.  The impact of treatment condition and the lagged effects of PTSD symptom severity and alcohol use on changes in alcohol craving.

Authors:  Antonia N Kaczkurkin; Anu Asnaani; Elizabeth Alpert; Edna B Foa
Journal:  Behav Res Ther       Date:  2016-02-15

6.  A Comparison of Markov and Discrete-Time Microsimulation Approaches: Simulating the Avoidance of Alcohol-Attributable Harmful Events from Reduction of Alcohol Consumption Through Treatment of Alcohol Dependence.

Authors:  Philippe Laramée; Aurélie Millier; Thor-Henrik Brodtkorb; Nora Rahhali; Olivier Cristeau; Samuel Aballéa; Stephen Montgomery; Sara Steeves; Mondher Toumi; Jürgen Rehm
Journal:  Clin Drug Investig       Date:  2016-11       Impact factor: 2.859

7.  Concurrent treatment of posttraumatic stress disorder and alcohol dependence: Predictors and moderators of outcome.

Authors:  Laurie J Zandberg; David Rosenfield; Carmen P McLean; Mark B Powers; Anu Asnaani; Edna B Foa
Journal:  J Consult Clin Psychol       Date:  2015-10-12

8.  The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective.

Authors:  Thor-Henrik Brodtkorb; Melissa Bell; Adam H Irving; Philippe Laramée
Journal:  CNS Drugs       Date:  2016-02       Impact factor: 5.749

9.  Predictors of dropout in concurrent treatment of posttraumatic stress disorder and alcohol dependence: Rate of improvement matters.

Authors:  Laurie J Zandberg; David Rosenfield; Elizabeth Alpert; Carmen P McLean; Edna B Foa
Journal:  Behav Res Ther       Date:  2016-03-03

10.  The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study.

Authors:  Ofra Sarid-Segal; Joanna Piechniczek-Buczek; Clifford Knapp; Maryam Afshar; Eric Devine; Laurie Sickles; Emma Uwodukunda; Courtney Richambault; Jillian Koplow; Domenic Ciraulo
Journal:  Am J Drug Alcohol Abuse       Date:  2008       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.